D. Scott McMeekin

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass

Richard G. Moore, D. Scott McMeekin, Amy Brown et al. · Gynecologic Oncology · 2008 · 866 citations

Medicine, Gynecology, Oncology +15

Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study

Bradley J. Monk, Michael W. Sill, D. Scott McMeekin et al. · Journal of Clinical Oncology · 2009 · 691 citations · Full text

Medicine, Gynecology, Oncology +15

Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study

Harry J. Long, Brian N. Bundy, Edward C. Grendys et al. · Journal of Clinical Oncology · 2005 · 557 citations

Medicine, Gynecology, Oncology +13

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer

Marcus E. Randall, Virginia L. Filiaci, D. Scott McMeekin et al. · Journal of Clinical Oncology · 2019 · 328 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

Carol Aghajanian, Michael W. Sill, Kathleen M. Darcy et al. · Journal of Clinical Oncology · 2011 · 319 citations · Full text

Medicine, Gynecology, Oncology +16